We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-5.1%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$175M
AUM Growth
+$45.5M
Cap. Flow
+$136M
Cap. Flow %
77.72%
Top 10 Hldgs %
99.68%
Holding
12
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
+$146M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.69M

Sector Composition

Rank Sector Weight
1 Healthcare 56.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
1
Amarin Corp
AMRN
$292M
$51.1M 29.12%
404,374
– –
RNA
2
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$41M 23.37%
+6,213,924
New +$146M
PTLA
3
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$33.2M 18.92%
1,240,917
– –
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.78B
$26.4M 15.02%
3,600,000
– –
CEMP
5
DELISTED
Cempra, Inc.
CEMP
$8.21M 4.68%
714,285
– –
ACHV icon
6
Achieve Life Sciences
ACHV
$667M
$5.61M 3.2%
274
– –
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
$4.32M 2.46%
291,902
– –
ANTH
8
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.76M 1%
54,749
– –
GWPH
9
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.74M 0.99%
102,200
– –
HPTX
10
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$1.63M 0.93%
62,500
– –
ZLCS
11
DELISTED
ZALICUS INC COM NEW
ZLCS
$564K 0.32%
78,967
– –
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$36.2B
– –
-313,053
Closed -$9.69M

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q3 2013 Portfolio in Review

As of Q3 2013, Abingworth held 12 positions worth $175M, up 35% from $130M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Abingworth deployed $136M of net new capital in Q3 2013, opening 1 new position. Its largest new stake was PROSENSA HLDGS N V ORD SHS (NLD): 6,213,924 shares worth $41M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 75% a quarter earlier.

On the sell side, the most notable exit was Alnylam Pharmaceuticals, an estimated $9.69M sold.

  • Abingworth's largest Q3 2013 buy was PROSENSA HLDGS N V ORD SHS (NLD): 6,213,924 shares worth $41M.
  • Abingworth fully exited Alnylam Pharmaceuticals in Q3 2013, selling an estimated $9.69M.
  • Abingworth's ten largest holdings make up 100% of its $175M portfolio in Q3 2013.
  • Abingworth opened 1 new position and closed 1 in Q3 2013.
  • Abingworth's portfolio value rose 35% quarter-over-quarter to $175M.

Based on Abingworth's 13F filing for Q3 2013, filed 14 Nov 2013.